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Abstract: The main functional components of green tea, such as epigallocatechin gallate 
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG) and epicatechin (EC), are 
found to have a broad antineoplastic activity. The discovery of their targets plays an 
important role in revealing the antineoplastic mechanism. Therefore, to identify potential 
target proteins for tea polyphenols, we have taken a comparative virtual screening approach 
using two reverse docking systems, one based on Autodock software and the other on 
Tarfisdock. Two separate in silico workflows were implemented to derive a set of target 
proteins related to human diseases and ranked by the binding energy score. Several 
conventional clinically important proteins with anti-tumor effects are screened out from the 
PDTD protein database as the potential receptors by both procedures. To further analyze the 
validity of docking results, we study the binding mode of EGCG and the potential target 
protein Leukotriene A4 hydrolase in detail. We indicate that interactions mediated by 
electrostatic and hydrogen bond play a key role in ligand binding. EGCG binds to the 
enzyme with certain orientation and conformation that is suitable for nucleophilic attacks by 
several electrical residues inside the enzyme’s activity cavity. This study provides useful 
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information for studying the antitumor mechanism of tea’s functional components. The 
comparative reverse docking strategy presented generates a tractable set of antineoplastic 
proteins for future experimental validation as drug targets against tumors. 
Keywords: tea polyphenols; reverse docking; target protein; binding mode; virtual screening 
 
1. Introduction  
Green tea is a popular beverage worldwide, and it has been found to have a relatively strong 
antineoplastic effect. The main active components of green tea are tea polyphenols composed of 
multiple catechins, such as EGC, ECG, EC and mainly EGCG. Numerous studies have shown that 
ECGC has a strong, complicated anti-tumor effect, including inhibiting tumor growth and inducing 
apoptosis, as well as inhibiting multi-targets growth, AKT/protein kinase B signaling pathway and so on. 
But the detailed mechanism is still unclear. Recent researches have indicated that cell signal transduction 
is bound up with tumor transformation and development [1]. In signal transduction pathways, the 
interactions between tea polyphenols, a signal transduction molecule, and their target receptors play a 
key role in cancer prevention. Moreover, designing targeted drugs for key receptor molecules in signal 
transduction pathways is a promising method for tumor therapy. 
However, although researchers have been looking for EGCG receptors over the years, possible 
receptors remain a big controversy nowadays. Recent studies have reported that EGCG can bind to the 
67 kDa laminin receptor (67LR) related to cancerometastasis [2,3], but Adachi et al. indicate that EGCG 
may not directly bind to the cell surface receptor [4]. In contrast to EGCG, studies on ECG, EGC and EC 
have rarely been reported, especially regarding their biological activity mechanism. All of these studies 
still need further investigation by large-scale randomized trials.  
Therefore, how to search for the molecular targets of tea polyphenols has effectively become an 
important and challenging task. Using proteomic profile and pharmacokinetic approach to identify the 
drug targets among thousands of candidate macromolecules has been proved to be laborious and 
time-consuming [5–8]. Therefore, some researchers resort to computing methods such as virtual 
screening to facilitate the experiment. However, the traditional virtual screening based on receptors 
usually contains two parts: the docking procedure and a drug molecular database. With the increased 
number of known protein structures, a new docking method called reverse docking was developed, in 
which docking is carried out by searching a protein database instead of a drug molecular database. For 
example, Chen, et al. successfully developed INVDOCK [9], a reverse docking system to study drug 
toxicity. Li, et al. developed a reverse docking web server, Tarfisdock [10], and used it to identify drug 
targets. These pioneering researches indicate that reverse docking procedures can be used to identify 
the target proteins of tea polyphenols. The above-mentioned reverse docking systems are both based on 
the widely used docking program, DOCK, and use ligand-protein interaction energy to assess the 
docking results [11]. Yet another popular docking program, Autodock [12], which employed a more 
precise score function and different algorithms, has not been tried for this purpose. A number of studies 
have proved that the ligand-protein binding mode predicted by Autodock agrees well with 
experimental results [13–16]. So Autodock could also be used for reverse docking purposes and we Int. J. Mol. Sci. 2011, 12                 
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develop a reverse docking system based on it in this research. As to the protein database, all the records 
in PDB database are original experimental data, they cannot be directly used for docking calculations, 
therefore secondary databases must be developed for docking programs, such as the Potential Drug 
Target Database PDTD [17], a comprehensive network database that contains more than 1100 3D 
protein structures and covers 15 therapeutic areas including tumor therapy.  
In this research, we take a comparative virtual screening approach which uses both the reverse 
docking system based on Autodock and the Tarfisdock system, to identify potential target proteins for 
tea polyphenols. Two separate in silico workflows are implemented to derive a set of protein targets 
ranked by the energy score from PDTD database, and all of the derived targets are related to human 
diseases, including tumors. To analyze the validity of docking results, we further explore the binding 
mode between tea polyphenols and their potential targets. This study may provide useful information for 
studying the antitumor mechanism of tea functional components. Our work also helps to design new 
targeted drugs with strong antineoplastic effects by providing the information about the binding 
mechanism of tea polyphenols to key putative receptor proteins.  
2. Results and Discussion 
Tea functional components studied in this work include epigallocatechin gallate (EGCG), epicatechin 
gallate (ECG), epigallocatechin (EGC) and epicatechin (EC). Their chemical structures are displayed in 
Figure 1. 
Figure 1. Structure of tea functional components EGCG, ECG, EGC and EC. 
 
2.1. Potential Protein Targets for EGCG 
Potential protein receptors for EGCG identified by our virtual screening procedures compared with 
experiment data are listed in Table 1. Computed binding free energies and experimental references for 
several EGCG-protein complexes are also included. The result shows that this strategy does screen out 
several EGCG receptors, including various types of cancer or other diseases related receptors. In addition, Int. J. Mol. Sci. 2011, 12                 
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five out of nine protein receptors verified by previous experimental report are discovered by   
virtual screening. 
Table 1. EGCG possible targets found by screening procedures compared with experiment. 
PDB_ID Target  Name 
Predicted 
by Procedures 
Implicated 
by Experiment 
Energy Score 
(kcal/mol) 
Reference or 
Related Disease 
3BCH  67 kD laminin receptor  Autodock  YES  −3.75 [2] 
7HVP HIV  protease  Autodock/Tarfisdock YES −5.01/−44.87 [18] 
1GRE glutathione  reductase  Autodock  YES  −6.80 [19,20] 
1IJH cholesterol  oxidase  Autodock  YES  −6.77 [21] 
8CAT catalase  Autodock  YES  −6.23 [22] 
1JNY eEF1-α Autodock  YES  −5.70 [3] 
1BOO DNA  methyltransferase  Autodock  YES  −4.66 [23] 
2OZO ZAP-70  Autodock  YES  −3.81 [24] 
2DQ7 Fyn  kinase  Autodock  YES  −4.91 [25] 
1HS6 Leukotriene  A4  Autodock/Tarfisdock NO  −5.22/−48.2 Esophagus  cancer 
1FT2 Farnesyl  protein  transferase  Autodock/Tarfisdock NO  −4.1/−44.94 Cancer/Tumour 
1UTR Mammalian  PCB-binding protein  Autodock  NO  −7.19 Lung  Cancer 
1JVM  Voltage-Gated Potassium Channel  Autodock  NO  −6.58 Cardiomyopathie 
1OG5 CYP450  Autodock  NO  −6.49 Tumour 
1VKG Histone  deacetylase  Autodock  NO  −5.63 Tumour 
1OOQ Dihyrofolate  reductase Tarfisdock NO  −46.42 Tumour 
1IYH  Hematopoietic Prostagladin Synthase  Tarfisdock  NO  −44.50 Cancer 
1PY5  TGF-beta receptor type I  Tarfisdock  NO  −44.33 Renal  carcinoma 
Fourteen potential receptors whose binding energies rank in the top 3%–2% by Autodock and 
Tarfisdock, respectively are listed in Table 1. Among them, eight receptors are screened out by 
Autodock alone and three by Tarfisdock alone. Three receptors, HIV protease, Leukotriene A4 and 
Farnesyl protein transferase are screened out by both software. To our delight, HIV protease is a 
valuable target of EGCG which has been implicated experimentally, and Leukotriene A4 and Farnesyl 
protein transferase are both likely to be important targets for EGCG. Four potential protein receptors, 
glutathione reductase, catalase, cholesterol oxidase and eEF1-α identified by Autodock have supporting 
experimental evidence. Anti-oxidation experiments in vivo have shown that EGCG plays a protective 
and prothetic role of intracellular GSH [19,20] and catalase [22]. It also interacts with cholesterol 
enzymes to inhibit the absorption of cholesterol [21]. A recent report indicates that silencing of eEF1-α 
in tumor cells results in the abrogation of EGCG-induced tumor growth inhibition in vivo [3]. It is of 
interest that many predicted EGCG-binding proteins are associated with cancers or tumors. For 
example, Histone deacetylase is perceived as a new important antitumor target in recent years; and some 
experimental results indicate that the inhibition of prostagladin D synthase may improve the symptoms 
of prostate cancer cachexia [26] and the expression of TGFβ-R-I can act as an indicator of  
renal carcinoma [27]. However, more experiments are needed to verify EGCG binding targets found in 
our work. 
Some proteins which might react with EGCG according to experimental data, such as 67 kD laminin 
receptor, ZAP-70 and Fyn kinase, are not found in the top 3% rank by our screening system, but they Int. J. Mol. Sci. 2011, 12                 
 
5204
also have weak binding-active with EGCG (see Table 1). The main reason for the absence of these 
potentailreceptors may be that both Autodock and Tarfisdock do not take the current flexibility of 
protein conformation into account. 
2.2. Potential Protein Receptors for ECG, EGC and EC 
The structures of tea functional components other than EGCG, such as ECG, EGC and EC are 
similar to EGCG. They may also possess certain biological activity. Therefore, virtual screening of their 
potential protein receptors is also performed. Co-receptors of these four tea polyphenols are listed in 
Table 2, which rank in top 2% of the targets identified by Autodock sorted by their binding energies. We 
note that some familiar clinical protein targets can bind to all of the 4 types of catechins according to this 
list, such as Cytochrome reductase P450 and Oxidosqualene cyclase. It indicates that ECG, EGC, and 
EC may also have the same anti-tumor effect as EGCG and could reduce cholesterol to some degree. It 
suggests that catechins may act on cytokine and key drug metabolism enzymes that involve in steroid 
hormone biosynthesis. They may have a potential effect on hypercholesterolemia, cardiac disease,  
and various inflammatory diseases. These results also need further experimental evidence Besides this, 
voltage-gated potassium channels, phospholipase A2, FK506 tacrolimus binding protein, and other several 
receptors can also bind to catechins to some extent. In addition, the structure between ECG and EGCG 
differs by only one hydroxyl group on the benzene ring, therefore they have relatively more co-receptors. 
Table 2. Potential co-receptors of 4 types of Tea-polyphenols screened by Autodock. 
Target Name 
4 Types of Tea-Polyphenols 
EGCG EGC ECG EC 
CYP450  √  √  √  √ 
Oxidosqualene cyclase  √  √  √  √ 
Voltage-Gated Potassium Channel  √  √ —  √ 
Phospholipase A2  √  √  √  √ 
FK506 binding protein  √ —  √  √ 
Dihyrofolate reductase  —  √  √  √ 
Leukotriene A4 hydrolase  √ —  √ — 
PARP(Poly ADP-Ribose Polymerase)  √  √  √ — 
Protoporphyrinogen oxidase  √  √  √ — 
Ornithine Aminotransferase  — —  —  √ 
1,2-Cyclooxygenase  — —  —  √ 
histone deacetylases (HDACs)  — — √  √ 
Amino acid oxidase  — — √  √ 
Glutamic acid receptor-2  —  √ —  — 
Mammalian PCB-binding protein  √ —  √ — 
Fatty acid-binding protein (FABP)  √ —  √ — 
Catalase  √  √ —  — 
2.3. Comparing Screening Results of Autodock and Tarfisdock 
Autodock and DOCK are both famous free software widely used in drug design field. Based on 
DOCK, Tarfisdock now works as a web server which is more convenient for screening drug targets Int. J. Mol. Sci. 2011, 12                 
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than Autodock. As mentioned above, the two molecular docking procedure Autodock and DOCK  
have their respective characteristics. Autodock uses Lamarckian genetic algorithm [12] and a more 
comprehensive scoring function which takes into account of hydrogen bonding and solvation free 
energy [28], while DOCK uses Fragment growth method (Systemic searching method) and a scoring 
function composed of non-bond interaction energy terms [10,11] which only takes van der Waals 
interaction and electrostatic interaction into consideration. For these reasons, Tarfisdock finishes the 
whole protein database search within 19–28 h depending on the flexibility of tea polyphenols, while 
Autodock should need 27–33 days in this work. To make our result more reliable, we compare virtual 
screening results of Autodock and DOCK to get common receptors for tea polyphenols found by  
both methods. 
Potential receptors for tea polyphenols identified by both procedures are listed in Table 3. According 
to the results listed in the table, the best EGCG-binding receptors are Leukotriene A4 hydrolase, farnesyl 
protein transferase (FPT) and HIV protease etc. EGC most likely combines with FKBP tacrolimus 
protein, glutamate carboxypeptidase II, etc. Squalene oxide cyclase and Leukotriene A4 hydrolase are 
the most potential protein targets for ECG. Squalene oxide cyclase is the only receptor for EC 
recognized by both Autodock and Tarfisdock. 
Table 3. The most possible targets screened by Autodock and Tarfisdock (top 3%). 
Ligand 
Name 
PDB_ID 
Score Tarfisdock 
（kcal/mol） 
Score Autodock 
（kcal/mol） 
Receptor Name 
EGCG 
1HS6  −48.21  −5.22 Leukotriene  A4  hydrolase 
1FT2  −44.94  −4.10 Farnesyl  protein  transferase 
7HVP  −44.87  −5.01 HIV  protease 
1Y79  −44.11  −3.96 Dipeptidyl  peptidase 
EGC 
1YTV  −36.44  −5.66 Vasopressin  V1a  receptor 
1Q5M  −35.83  −3.32 
Alpha hydroxysteroid 
dehydrogenase 
1NR5  −35.24  −4.01 3-dehydroquinate  Synthase 
1Y79  −35.19  −3.77 Peptidyl  dipeptidase 
2C6C  −48.27  −3.31  Glutamate carboxypeptidase II
1TCO  −43.82  −6.07  FK506 binding protein 
ECG 
1W6K  −38.06  −6.07 Oxidosqualene  cyclase 
1HS6  −46.21  −5.74 Leukotriene  A4  hydrolase 
EC 1W6K  −38.06  −6.07 Oxidosqualene  cyclase 
The screening results of the 4 types of catechins by two different software are different. EGC has the 
highest match rate, the number of common receptors divide by total number of receptors found, with 
match rate of 27.30%, EGCG followed by 18.20%, EC only by 4.50%. The difference is mainly due to 
the different receptor pockets-determining methods, conformational search algorithms and energy 
scoring functions used by these two software. 
The binding free energies between protein and ligand are calculated by an energy scoring function in 
Autodock as shown by Equation 1. Int. J. Mol. Sci. 2011, 12                 
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In the above equation, the total binding energy is composed of van der Waals energy, hydrogen bond 
energy, electrostatic energy, ligand rotary energy and solvation free energy. In contrast, Tarfisdock 
only focuses on the interaction energies whose energy function is shown by Equation 2.  
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In Equation (2), the total energy is composed of van der Waals energy and electrostatic energy. In 
both Equation (1) and (2), each term is a double sum over ligand atoms i and receptor atoms j; rij is the 
distance between atom i and atom j; Aij,  Bij,  Cij and Dij are van der Waals repulsion and attraction 
parameters, respectively; a and b are the van der Waals repulsion and attraction exponents, respectively; 
qi and qj are point charges on atoms i and j; D and ε(r) are dielectric constant; and 332.0 is the factor that 
converts the electrostatic energy into kcal/mol. 
Comparing these two docking procedures’ results, we find that EGCG and ECG share a common best 
receptor: Leukotriene A4 hydrolase, for its lower binding energy get by both procedures. Therefore, we 
tried to explore the binding mode between these two kinds of catechins and leukotriene A4 hydrolase. 
2.4. Docking Results for the Original Ligand BES in Leukotriene A4 hydrolase Crystal Structure  
Myocardial infarction is recognized as the world's leading cause of death. Hakonarson, H. et al. 
indicated that mutants correlating with two genes in leukotriene pathway are associated with the risk of 
myocardial infarction [29]. 13% patients carried Leukotriene A4 (LTA4) hydrolase mutant gene. This 
hydrolase is composed of a group of bioactive enzymes, whose genetic polymorphism may increase the 
risk of myocardial infarction. Moreover, it plays an important role in the regulation of low-sensitivity 
reactions and inflammation. Besides this, its overexpression in esophageal adenocarcinoma cells is also 
one of the early symptoms of esophageal adenocarcinoma. 
LTA4 hydrolase is a kind of zincic metalloprotease with intrinsic aminopeptidase activity, containing 
610 amino acid residues, 43 α-helix, 7 β hairpin and 22 β sheet. Although numerous applications have 
demonstrated the success of Autodock in docking simulations for reproducing experimental binding 
structures, it remains a question whether it works for the particular biological system of interest. To 
examine the reliability of the docking method, the original ligand BES from a ligand-LTA4 hydrolase 
complex structure is removed from the PDB file and docks back to the ligand binding site using the same 
docking strategy as EGCG. The superposition of the structures of the docking simulation results and that 
of the crystallographic structure complex is shown in Figure 2. As shown in Figure 2, Arg563 forms a 
hydrogen bond (O…H—N) with the oxygen atom O1 of the original bound ligand and O4 of the 
docking conformation respectively. Nonetheless, LTA4 hydrolase forms 3 hydrogen bonds with the 
docked conformation similarly to the original bound structure, with the error of bond length within  
0.29 Å. The root-mean-square deviations of all heavy atoms of BES between the docked poses and the Int. J. Mol. Sci. 2011, 12                 
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crystallographic coordinates range from 0.3 to 1.5 Å. Apart from that, the docked pose is overall very 
close to the experimental structure. These results show that the docking method is able to reproduce the 
experimental binding structure of ligand-LTA4 hydrolase complex. 
Figure 2. The docked ligand BES compared with its original bound structure in 
crystallographic complex. It showed that the docked structure is very close to the 
experimental structure: Blue: original bound structure in crystal complex (left figure); 
Yellow: the docked conformation (right figure).  
 
2.5. Binding Mode between Leukotriene A4 Hydrolase and EGCG 
The docking conformations of BES/EGCG and Leukotriene A4 hydrolase complexes predicted by 
Autodock are given in Figure 3, with the binding free energy −6.8 and −5.22 kcal/mol respectively. As 
shown in Figure 3(a), EGCG binds to Leukotriene A4 hydrolase in the active cavity where the original 
substrate BES located. In Figure 3(b) and (c), residues such as TYR383 and GLU296, colored in marine 
or orange, represent the catalytic center of the leukotriene A4 hydrolase. From Figure 3(b), we can see 
the binding mode of EGCG and Leukotriene A4 hydrolase. Three benzene ring planes of EGCG are 
located in the active cavity composed of electrical amino acids such as GLU348, TYR378, SER380, 
TYR383, ARG568, GLU296, LYS565, ARG563, ARG537, etc. On the other hand, polar residues 
GLU348, TYR383, GLU296 and ARG568, colored in marine, form 3 hydrogen bonds O…O—H and 1 
hydrogen bond N…O—H with four hydroxyl groups of EGCG, with bond distance of 2.58 Å no bold, 
2.11 Å, 2.86 Å and 3.14 Å, respectively. The interaction between Leukotriene A4 hydrolase and its 
original ligand is shown in Figure 3(c), where residues GLY269, ARG563, ARG565 colored in orange 
form 1 strong hydrogen bond H…O—H and 2 strong hydrogen bonds N—H…O with ligand BES. The 
bond distances are 1.96 Å, 1.84 Å, and 1.70 Å, respectively. 
Our analysis shows that the interactions mediated by electrostatic and hydrogen bonds play a key role 
in the binding of EGCG and Leukotriene A4 hydrolase. It suggests that EGCG may bind to leukotriene 
A4 hydrolase catalytic site through electrostatic and hydrogen bonds interactions, thus prevents the 
exposure of the catalytic site to the substrate BES and acts as a competitive inhibitor of the enzyme.  Int. J. Mol. Sci. 2011, 12                 
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Figure 3. Micro environment of the bind site of EGCG/BES and Leukotriene A4 hydrolase. 
(a) EGCG (yellow) binds to Leukotriene A4 hydrolase in the active cavity (catalytic center 
and binding domain) where the original ligand BES (red) located; (b) Residues GLU348, 
SER380, TYR383, TYR378, ARG563, ARG565, ARG568, GLU296 and ARG537 make up 
a electrostatic cavity; hydroxyl groups of EGCG form hydrogen bonds with the surrounding 
amino acids GLU348, TYR383, GLU296 and ARG568 (blue); (c) The original ligand 
formed 3 strong hydrogen bonds with residues GLY269, ARG563, and ARG565 (orange). 
 
(a) 
 
(b) 
 
(c) 
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3. Experimental Section  
3.1. The Three-Dimensional Structures of Tea Polyphenols and Drug Targets 
Crystal structure of the four kinds of tea polyphenols: (EGCG.pdb, EGC.pdb, ECG.pdb, EC.pdb) 
come from MMsINC database (http://mms.dsfarm.unipd.it/MMsINC/search/ligandsearch.php). Crystal 
structure of receptors: 1044 kinds of potential drug target molecules are selected from PDTD database 
(http://www.dddc.ac.cn/pdtd/). Polar hydrogen atoms and Kollman charges are added to all mol2 files of 
the receptors. All of the potential drug targets in PDTD database are related to cancer, diabetes and other 
diseases, including 79.8% of the enzymes, 4.6% of the receptor, 3.5% of the monoclonal antibody, 3.3% 
of the regulatory factors and hormones. Three experimental implicated targets of EGCG that are absent 
in PDTD are obtained from PDB database. 
3.2. Reverse Docking Procedure Using Autodock and Tarfisdock 
： Reverse docking based on Autodock4 we use a reverse docking system by providing a series of 
cshell scripts independently to invoke Autodock core code. These scripts will combine the docking 
procedure with a protein database and dock a mall molecule to all proteins in the database one by one 
automatically. The corresponding receptors of these four mall molecules (EGCG, EGC, ECG, EC) are 
screened by this system using PDTD as its protein database. Gasteiger charge and all the hydrogen 
atoms (polar and non-polar) are added to receptors initially. For docking, the grid box size of the 
receptor molecules is 81 * 81 * 81 Å
3, the grid spacing is 0.375 Å, the box located at the center of the 
receptor. The procedure uses optimizing Lamarckian genetic algorithm for global searching and uses 
Solis & Wets simulated annealing for local searching. Global optimization generates 500 randomly 
initial conformations for each ligand, the maximum energy evaluation number is 2.5 × 10
7 and the 
maximum offspring number is 2.7 × 10
4. Two independent GA calculations are carried out. For the Solis 
& Wets simulated annealing setting, the maximum number of iterations is 50, each iteration is set to 
carry four receive and four refused steps, and the default setting is used for other parameters. The lowest 
docking energy value is used to assess screening results. 
Reverse docking based on DOCK4: Tarfisdock web service (http://www.dddc.ac.cn/tarfisdock/) is 
used. Virtual screening for potential receptors of tea polyphenols (EGCG , EGC, ECG, EC) is carried 
out by invoking DOCK4.0 to search PDTD database from this web interface. 
4. Conclusions 
In this study, a comparative reverse docking approach using Autodock and Tarfisdock is taken to 
identify the potential receptors for green tea bioactive substances such as EGCG, EGC, ECG and EC. 
The results show that: (1) a number of receptors of EGCG identified by our method such as Glutathione 
reductase, Catalase and eEF1-α etc. have been verified by experiments. While some other potential 
receptors such as Squalene oxide cyclase, FPTase, Leukotriene A4 hydrolase and FKBP, are either 
conventional clinical targets with anti-tumor effects or target enzymes of drug design; (2) Several 
receptors identified by two different docking procedures are proposed as best putative targets for four 
types of catechin; (3) We further explore the binding mode between the most potential receptor Int. J. Mol. Sci. 2011, 12                 
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Leukotriene A4 hydrolase and EGCG. We propose that EGCG binds to the Leukotriene A4 hydrolase 
active site with certain orientation and conformation so that it may acts as a competitive inhibitor of that 
enzyme. Structure analysis shows that electrostatic interaction and hydrogen bonding play an important 
role in their binding process. This study provides important information for studying EGCG and its 
derivatives’ antitumor mechanism and new targeted drugs design. 
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